Cardiokinetix

CardioKinetix, Inc. is a medical device company based in Menlo Park, California, founded in 2003. The company specializes in catheter-based therapies for heart failure patients, focusing on innovative solutions that enhance cardiac function and improve quality of life. The flagship product, the Parachute® Ventricular Partitioning Device, is designed to treat ischemic heart failure by isolating damaged areas of the left ventricle. This minimally invasive device is delivered via catheter and aims to improve cardiac output and alleviate symptoms. CardioKinetix is actively conducting clinical trials, including the U.S. randomized PARACHUTE IV trial, to validate the device's safety and efficacy. The company also collaborates with medical animation firms to create educational materials for healthcare providers and patients. CardioKinetix serves cardiologists, cardiac surgeons, and healthcare providers involved in heart failure management, with a focus on hospitals and medical centers. The company has secured significant funding to support its clinical development and commercialization efforts globally.

• Employees 8
• Founded 2002
• Annual Revenue $5000000
• Total Funding $89500000